Piperazines are essential elements in drug design. Currently MDL© Drug Data Report database contains over 11 800 structures bearing the piperazine moiety. Enamine would like to present our set of exclusive "small" piperazines - compounds with low molecular weight (below 190 Da).
These building blocks could be used for synthesis of new drug-like screening compounds via transformations typical for secondary amines.